Affinity Asset Advisors »

Alkermes shares owned by Affinity Asset Advisors

Quarter-by-quarter ownership of Alkermes (ALKS) shares owned by Affinity Asset Advisors from 13F filings

Historical chart of Affinity Asset Advisors investment in Alkermes

Tip: Access up to 7 years of quarterly data

All positions including Alkermes held by Affinity Asset Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Alkermes by Affinity Asset Advisors

Quarter filed Position value Share count Share price at filing
2023-09-30 $8.4M 300k 28.01

More positions owned by Affinity Asset Advisors

Teva Pharmaceutical Inds Sponsored Ads (TEVA)
Apogee Therapeutics (APGE)
Establishment Labs Holdings Ord (ESTA)
Cymabay Therapeutics
Immunovant (IMVT)
Bridgebio Pharma Note 2.500% 3/1 (Principal)
Cerevel Therapeutics Hldng I (CERE)
Arcellx Common Stock (ACLX)
Crinetics Pharmaceuticals In (CRNX)
Madrigal Pharmaceuticals (MDGL)
Xenon Pharmaceuticals (XENE)
Alkermes SHS Call Option (ALKS)
Kura Oncology (KURA)
Astria Therapeutics (ATXS)
Morphic Hldg (MORF)

View all positions for Affinity Asset Advisors

Top funds holding Alkermes

Vanguard Group
Wellington Management Company
Johnston Asset Management Corp.
PRIMECAP Management Company
Bank of New York Mellon
Dimensional Fund Advisors
Charles Schwab Investment Management
Artisan Partners Limited Partnership
Norges Bank Investment Management
Westfield Capital Management Company
T. Rowe Price Associates
Jupiter Asset Management
Goldman Sachs Group
Bank of America Corporation
Jacobs Levy Equity Management

View all funds holding Alkermes